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Significance of 
Pathophysiology
Shingles can be diagnosed by the 
distinctive appearance and manifestation of 
the rash (Cohen, 2014).  Shingles is only 
contracted by the direct skin contact of an 
affected area with the rash and the rash will 
continue to be contagious until the lesions 
dry up.  Those who are contagious should 
to be instructed to avoid contact with 
anyone who has not had chickenpox, 
anyone who is immune compromised, and 
women who are pregnant (Cohen, 2014). 
Anyone who has not had the varicella 
vaccine or previously had chickenpox can 
contract chickenpox from someone infected 
with shingles (Cohen, 2014). 
Pathophysiology
Shingles is triggered by the recurrence 
of the chickenpox virus (herpes zoster) 
which, after initial infection, lies inactive in 
the anterior horn cells of peripheral sensory 
nerves, next to the spine (Lowth, 2013). 
After initial infection with chickenpox 
(varicella) the virus stays in a clinically 
dormant condition in the spinal and cranial 
sensory ganglia (Gupta & Farquhar, 2012). 
When the virus reactivates it goes back 
down nerve axons affecting the skin in the 
area of the nerve with the traditional 
painful rash (Lowth, 2013). 
“The zoster vaccine (Zostavax) is a one-
dose, high-potency, live-attenuated 
vaccine that boosts VZV-specific cell-
mediated immunity and was licensed in 
the USA in 2006 for adults aged 60 years 
and older” (Gan et al., 2013, p. 83).  
Many insurance companies will not cover 
the cost of the Zostavax vaccination, since 
the median wholesale cost of a single 
dose is one hundred and ninety-four 
dollars (Kanbayashi & Hosokawa, 2013). 
Unfortunately, there is nothing that can 
entirely prevent PHN, but in a study of 
38,000 adults aged sixty and older who 
received vaccination, the vaccine was 
shown to decrease the occurrence of 
herpes zoster by fifty-one point three 
percent (Lowth, 2013). 
There are contraindications to taking 
the vaccination, but they are mainly 
barriers such as patient accessibility to the 
vaccine, being unable to afford the 
expense of the vaccine, and the education 
needs of patient’s and provider’s (McCall 
& Parker, 2013).  Health care 
professionals and nurses have 
opportunities to decrease these barriers by 
initiating plans to find qualified patients, 
supplying patient education related to 
vaccine cost, and to help patient’s by 
simplifying access to the vaccine (McCall 
& Parker, 2013).
Conclusion
In conclusion, shingles is a very 
painful,  debilitating illness which can 
significantly affect a persons quality of 
life.  Anyone who has had chicken pox 
can develop shingles.  The most 
successful way to decrease the probability 
of developing shingles and all of the 
possible complications and expenses 
associated to the illness is to receive 
vaccination (McCall & Parker, 2013).
In the United States nearly one out of 
three people in their lifetime will develop 
shingles, which also recognized herpes 
zoster or zoster ("CDC," 2016).  In the 
United States there are an estimated one 
million cases of shingles each year 
("CDC," 2016).  Shingles, also known 
herpes zoster, is triggered by reactivation 
of the varicella zoster virus (Kochhar, 
2014).  Shingles are described as vesicular 
skin lesions, which are very painful and is 
usually directly related with an underlying 
nerve pathway (Oakley & Goodband, 
2013).  Shingles has affected several of the 
author’s family members and she has often 
wondered if family history of shingles pre-
disposes her to a shingles outbreak.  The 
author also seeks to gain knowledge about 
the effectiveness and benefits of receiving 
the shingles vaccination to help determine 
her decision in receiving the vaccination 
herself.
Disease Process 
and Those Effected
Varicella-zoster virus (VZV) causes 
chickenpox (varicella), and a person’s 
initial infection causes a systemic illness 
that involves an extensive vesicular rash 
that is extremely contagious in the early 
stages that is usually accompanied with a 
fever and is more frequently observed in 
children (Corden, 2014).  Herpes zoster, 
also recognized as shingles, which is a 
double-stranded DNA herpes virus, results 
from the reactivation of varicella zoster 
virus (VZV) (Gupta & Farquhar Smith, 
2012).  Shingles is a disorder observed 
more frequently in older people and those 
who due to illness or medications, are 
immunocompromised (Corden, 2014).  In 
person’s over the age of eighty-five, it is 
estimated that the risk of developing herpes 
zoster increases to fifty percent in those 
who have not been vaccinated and the risk 
is greater among females (Cohen, 2014). 
People who have never had chickenpox 
or the varicella vaccine, low birth weight 
or premature infants, are also at greater risk 
of developing shingles (McCall & Parker, 
2013).
Shingles is described as a vesicular 
rash on one side of the body, which is 
painful and has a dermatomal 
distribution (a dermatome being the area 
of skin supplied by a single, particular 
nerve root) (Oakley & Goodband, 2013). 
The usual location for shingles to 
develop in people who are not 
immunocompromised is the thoracic 
nerves, so consequently in the skin 
covering the ribs, but shingles can 
ultimately affect any nerve root (Corden, 
2014).  Shingles can cause scarring and 
can also affect the nerves in the ears and 
eyes (Corden, 2014).  The virus 
reproduces and causes necrosis and 
inflammation in the dermatomal skin, the 
time period taken by the virus to 
reproduce is known as the prodome 
period (Gupta & Farquhar Smith, 2012).
Signs & Symptoms
In the prodromal phase a burning, 
itching, sharp pain occurs a few days 
before in the areas where the shingles 
vesicles or rash develops (Shannon, 
Anderson, & Damle, 2012).  Many 
people describe prodromal pain where 
skin lesions consequently appear (Gupta 
& Farquhar Smith, 2012). The prodromal 
period usually continues for several days 
but may prolong for a week or more 
(Gupta & Farquhar Smith, 2012).
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Implications for 
Nursing Care
Complications of 
Shingles
“Erythematous, small, well-defined and 
discolored areas of skin (macules) and solid 
rounded bumps in the skin, (papules) 
develop in the early phases of shingles, 
followed by fluid-filled sacs, (vesicles) 
which ultimately crust over” (Corden, 2014, 
p. 60).  Patients should be in contact 
isolation while hospitalized for a herpes 
zoster outbreak because open lesions that 
result from the herpes zoster rash are 
deemed contagious until the lesions are 
dried because the discharge contains the 
varicella zoster virus (Shannon et al., 2012).  
The blisters or vesicles will start to dry and 
establish scabs that will usually begin to 
come off around two to three weeks 
(McCall & Parker, 2013).  Once the rash 
resolves, there may be subsequent scarring 
and changes in the pigment of the skin 
(Corden, 2014).
Prevention & 
Treatment
“Prevention strategies include primary 
varicella vaccine to decrease the incidence of 
chicken pox, zoster vaccine to decrease the 
incidence of acute herpes zoster, antiviral 
medications to treat acute zoster, and 
aggressive pain control for acute herpetic 
neuralgia” (Philip & Thakur, 2011, p. 767).  
To reduce the severity of a shingles outbreak 
antivirals such as acyclovir, valacyclovir, 
famciclovir are used (McCall & Parker, 2013). 
Antiviral medications help to reduce the 
intensity of herpes zoster pain in the acute 
phase and its effect on quality of life and help 
to decrease the extent of the herpes zoster 
outbreak period (Gan, Tian, & Tey, 2013).
Antiviral medication should be taken within 
seventy-two hours of the first rash 
development to achieve the maximum effect 
(Corden, 2014). 
Antiviral medication is typically given to 
affected individuals who are either:
• Over 50
• Under 50 in either of the following 
categories:
1. immunocompromised.
2. demonstrating ophthalmic 
involvement.
3. symptomatic with 
moderate-to- severe pain or 
with a moderate- to-severe 
rash (Corden, 2014, p. 62).
Sufficient pain control is very important 
because herpes zoster can be extremely 
painful.  Herpes zoster pain can be separated 
into acute pain which can continue for up to 
thirty days, subacute pain lasting thirty to one 
hundred and twenty days, or chronic pain 
which lasts from three months after the rash 
heals or four months after the beginning of the 
prodromal period (Gupta & Farquhar Smith, 
2012).  The pain of acute herpes zoster can be 
decreased by the administration of 
corticosteroids, which enhances healing of 
lesions and helps people return to their daily 
routines faster (Gan et al., 2013).        
Acetaminophen or non-steroidal anti-
inflammatory drugs (NSAIDs) can be used 
alone or combined with tramadol or a weak 
opioid to manage mild to moderate pain 
(Kanbayashi & Hosokawa, 2013).  Opioids 
such as oxycodone or morphine can be 
given if pain is moderate to severe (Gan et 
al., 2013).  “If moderate to severe pain is 
not controlled with opioids, consider using 
gabapentin or pregabalin, tricyclic anti-
depressants (TCAs), or corticosteroids” 
(Gan et al., 2013, p 80).  Topical Capsaicin 
ointment can be used as well as lidocaine 
patches (Oakley & Goodband, 2013).
Shingles can cause complications in some 
people and are usually related to the 
patient’s personal risk factors and the site of 
the rash.  A shingles rash usually heals in 
ten to fourteen days but pain can linger for 
months or years (Lowth, 2013).  “Post-
herpetic neuralgia (PHN) is described as 
chronic pain, lasting three months or longer, 
with skin alterations in the supply of one or 
more sensory roots subsequent to herpes 
zoster infection” (Gupta & Farquhar Smith, 
2012, p. 181). 
PHN is the most common complication 
of shingles, which can continue for an 
extended period of time and considerably 
affect a person’s quality of life (Oakley & 
Goodband, 2013).  A risk factor of PHN is 
severe acute pain, efficient acute pain relief 
along with antiviral therapy may decrease 
the risk of developing PHN (Gan et al., 
2013).  PHN generally only affects the 
region of skin supplied by the nerve 
affected by the shingles outbreak, and is 
possibly a result of nerve injury by the virus 
(Lowth, 2013). 
“PHN most commonly involves thoracic
dermatomes, although in twenty percent of 
the patients, the ophthalmic division of the 
trigeminal nerve is involved” (Gupta & 
Farquhar Smith, 2012, p. 182).  Steroids are 
generally used to treat a shingles outbreak 
involving the nerves of the face or eyes 
(McCall & Parker, 2013).  Some other 
complications that occur may need to be 
treated with medications such as antibiotics, 
anti-depressants, and analgesics (McCall & 
Parker, 2013). 
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